Enobosarm vs Ligandrol

Enobosarm (D-tier) vs Ligandrol (C-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

Enobosarm · tier D

Enobosarm, also called ostarine or GTx-024, is an unapproved androgen-receptor SARM with short lean-mass signals and split registry-posted phase 3 lean-mass and function results.

Short randomized trials found lean-mass changes in selected older and cancer populations. POWER1 and POWER2 posted split lean-mass and stair-power responder patterns, and the record does not establish durable function, survival, athletic benefit, or long-term safety.

159 / 100 randomized and efficacy-evaluable phase 2 denominators · half-life not stated; no complete source-backed base PK set in the cited public outcome record · androgens

Ligandrol · tier C

Ligandrol, LGD-4033, or VK5211 is an unapproved androgen-receptor SARM with measured human PK, short lean-mass and hormone effects, and delayed registry-only hip-fracture results.

Ligandrol increased DXA lean mass in a short healthy-male study and in delayed sponsor registry results after hip fracture. Neither record established strength, mobility, independence, fewer falls or fractures, bodybuilding performance, fertility safety, or long-term organ safety.

108 / 79 hip-fracture participants started and with primary measurements · half-life 24 to 36 h in the 21-day oral study in healthy men · androgens

at a glance

• Enobosarm: tier D · 159 / 100 randomized and efficacy-evaluable phase 2 denominators
• Ligandrol: tier C · 108 / 79 hip-fracture participants started and with primary measurements

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.